Hussein A A, Hamidieh A A, Elhaddad A, Ramzi M, Othman T B, Hussain F, Dennison D, Ahmed P, Abboud M, Al-Ahmari A, Wahadneh A, Fathy J, Bekadja M-A, Al-Kindi S, Benchekroun S, Ibrahim A, Behfar M, Samra M, Ladeb S, Adil S, El-Solh H, Ayas M, Aljurf M, Ghavamzadeh A, Al-Seraihy A
Bone Marrow and Stem Cell Transplantation Program, King Hussein Cancer Center, Amman, Jordan.
Hematology, Oncology and SCT Research Center, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
Bone Marrow Transplant. 2017 Jan;52(1):120-125. doi: 10.1038/bmt.2016.209. Epub 2016 Sep 12.
To describe the hematopoietic stem cell transplantation (HSCT) activities for children in the Eastern Mediterranean (EM) region, data on transplants performed for children less than 18 years of age between 1984 and 2011 in eight EM countries (Egypt, Iran, Jordan, Lebanon, Oman, Pakistan, Saudi Arabia and Tunisia) were collected. A total of 5187 transplants were performed, of which 4513 (87%) were allogeneic and 674 (13%) were autologous. Overall, the indications for transplantation were malignant diseases in 1736 (38.5%) and non-malignant in 2777 (61.5%) patients. A myeloablative conditioning regimen was used in 88% of the allografts. Bone marrow (BM) was the most frequent source of stem cells (56.2%), although an increasing use of PBSC was observed in the last decade. The stem cell source of autologous HSCT has shifted over time from BM to PBSC, and 80.9% of autologous HSCTs were from PBSCs. The donors for allogeneic transplants were matched-related in 94.5% of the cases, and unrelated transplants, mainly cord blood (99%) in 239 (5.5%) cases. This is the first report to describe the pediatric HSCT activities in EM countries. Non-malignant disorders are the main indication for allogeneic transplantation. Frequency of alternate donor transplantation is low.
为描述东地中海(EM)地区儿童造血干细胞移植(HSCT)活动,收集了1984年至2011年期间八个EM国家(埃及、伊朗、约旦、黎巴嫩、阿曼、巴基斯坦、沙特阿拉伯和突尼斯)为18岁以下儿童进行移植的数据。共进行了5187例移植,其中4513例(87%)为同种异体移植,674例(13%)为自体移植。总体而言,移植指征为恶性疾病的患者有1736例(38.5%),非恶性疾病的患者有2777例(61.5%)。88%的同种异体移植采用了清髓性预处理方案。骨髓(BM)是最常见的干细胞来源(56.2%),不过在过去十年中观察到外周血干细胞(PBSC)的使用有所增加。自体HSCT的干细胞来源随时间从BM转向了PBSC,80.9%的自体HSCT来自PBSC。同种异体移植的供者在94.5%的病例中为匹配相关供者,在239例(5.5%)病例中为非相关供者,主要是脐血(99%)。这是第一份描述EM国家儿科HSCT活动的报告。非恶性疾病是同种异体移植的主要指征。替代供者移植的频率较低。